Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is the area under the curve (AUC) for GB241 and rituximab concentrations.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03003039
Study type Interventional
Source Nanjing Yoko Biomedical Co., Ltd.
Status Completed
Phase Phase 1
Start date June 5, 2017
Completion date May 20, 2019

See also
  Status Clinical Trial Phase
Completed NCT02900716 - Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Phase 1
Active, not recruiting NCT03068416 - CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy Phase 2
Recruiting NCT04023071 - FT516 in Subjects With Advanced Hematologic Malignancies Phase 1
Recruiting NCT04148430 - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy Phase 2
Completed NCT02933320 - BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia Phase 1/Phase 2
Active, not recruiting NCT03133221 - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Phase 2
Active, not recruiting NCT02741388 - A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP Phase 1
Recruiting NCT02300402 - Detection and Characterization of Residual Masses in Lymphomas
Terminated NCT02266147 - Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Phase 1/Phase 2
Terminated NCT00906841 - Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma Phase 2
Completed NCT00338494 - Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Phase 1
Recruiting NCT03281551 - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma Phase 1
Completed NCT03734601 - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Phase 2
Completed NCT00542919 - A Study for Patients With Non-Hodgkin's Lymphomas Phase 2
Recruiting NCT03740529 - A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Phase 1/Phase 2
Not yet recruiting NCT04877080 - CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL Phase 1
Completed NCT00299494 - Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Terminated NCT02055924 - Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas Phase 1
Terminated NCT00788606 - R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma Phase 2
Terminated NCT01300793 - Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide Phase 1